Quantitative Analysis of Salmon Calcitonin Hydroxyapatite Nanoparticle Permeation to substantiate Non-Invasive Bone Targeting via Sublingual Delivery
- PMID: 40102334
- DOI: 10.1208/s12249-025-03068-w
Quantitative Analysis of Salmon Calcitonin Hydroxyapatite Nanoparticle Permeation to substantiate Non-Invasive Bone Targeting via Sublingual Delivery
Abstract
We earlier reported comparable efficacy in bone parameters of sublingually administered salmon calcitonin hydroxyapatite nanoparticles (SCT-HAP-NPs) compared to the subcutaneous injection, in the ovariectomy rat model, despite a bioavailability of barely ~ 15%. We ascribed this intriguing finding to targeted bone delivery, facilitated by translocation of significant quantity of intact NP into systemic circulation. In the present study we track the translocation of FITC-SCT-HAP-NPs (~ 100 nm) across porcine sublingual mucosa using the Franz diffusion cell to validate our hypothesis. Confocal Laser Scanning microscopy (CLSM) established that SCT-HAP-NPs permeated into the deeper layers of sublingual porcine mucosal tissue. We confirmed the nanoparticles were present in the receptor medium of the Franz diffusion cell by DLS and TEM. We also demonstrate for the first time quantification of the NPs (%) translocated across the porcine mucosa, using the Amnis Image StreamX Mk II imaging flow cytometer. Computation revealed transport of ~ 60% of the FITC-SCT-HAP-NPs across mucosa in 2 h, substantiated that high NP concentrations could reach systemic circulation. Such high NP concentration in systemic circulation coupled with the small size (~ 100 nm) and the high bone affinity of HAP, validate our hypothesis of targeted bone delivery following sublingual administration. Furthermore, quantification of translocated NPs, which we demonstrate for the first time, would permit rational development of optimal targeted nanoparticulate carriers for delivery by noninvasive routes.
Keywords: Amnis image streamX Mk II imaging flow cytometer; Osteoporosis; Porcine sublingual mucosa; Quantification of intact NPs; Salmon calcitonin hydroxyapatite nanoparticles (SCT-HAP-NPs).
© 2025. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Conflict of interest statement
Declarations. Conflict of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT).Nanomedicine. 2020 Feb;24:102153. doi: 10.1016/j.nano.2020.102153. Epub 2020 Jan 25. Nanomedicine. 2020. PMID: 31988038
-
Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery.Drug Des Devel Ther. 2013 Aug 28;7:861-73. doi: 10.2147/DDDT.S47681. eCollection 2013. Drug Des Devel Ther. 2013. PMID: 24039397 Free PMC article.
-
Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles.Int J Pharm. 2019 Feb 25;557:170-177. doi: 10.1016/j.ijpharm.2018.12.053. Epub 2018 Dec 28. Int J Pharm. 2019. PMID: 30597264
-
Recent progress of rare earth doped hydroxyapatite nanoparticles: Luminescence properties, synthesis and biomedical applications.Acta Biomater. 2022 Aug;148:22-43. doi: 10.1016/j.actbio.2022.06.006. Epub 2022 Jun 5. Acta Biomater. 2022. PMID: 35675891 Review.
-
Sublingual drug delivery.Crit Rev Ther Drug Carrier Syst. 2008;25(5):449-84. doi: 10.1615/critrevtherdrugcarriersyst.v25.i5.20. Crit Rev Ther Drug Carrier Syst. 2008. PMID: 19062634 Review.
References
-
- Rabanel JM, Aoun V, Elkin I, Mokhtar M, Hildgen P. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. Curr Medi Chem. 2012;19(19):3070–102. https://doi.org/10.2174/092986712800784702 . - DOI
-
- Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review Nanomedicine: nanotechnology. Biol Med. 2005;1(3):193–212. https://doi.org/10.1016/j.nano.2005.06.004 . - DOI
-
- Bachhav SS, Dighe VD, Devarajan PV. Exploring Peyer’s patch uptake as a strategy for targeted lung delivery of polymeric rifampicin nanoparticles. Mol Pharm. 2018;15(10):4434–45. https://doi.org/10.1021/acs.molpharmaceut.8b00382 . - DOI
-
- Bachhav SS, Dighe VD, Kotak D, Devarajan PV. Rifampicin Lipid-Polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer’s patch uptake. Int J Pharm. 2017;532(1):612–22. https://doi.org/10.1016/j.ijpharm.2017.09.040 . - DOI
-
- Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, Qoronfleh MW. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):20. https://doi.org/10.1186/s40824-019-0166-x . - DOI - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous